Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 874-875

  Di Biagio, Antonio ^a   Rosso, Raffaella ^a   Siccardi, Marco ^b   D'Avolio, Antonio ^b   Bonora, Stefano ^b   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatitis C virus; Highly active antiretroviral therapy; Immunosuppressive drugs; Integrase inhibitor

Indexed keywords

AMPRENAVIR PHOSPHATE; CYCLOSPORIN; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; STEROID; TENOFOVIR; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; GRAFT RECIPIENT; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LETTER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE;

ANTI-HIV AGENTS; CYCLOSPORINE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PYRROLIDINONES; SERUM; TRANSPLANTATION;

EID: 70349456237     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp269     Document Type: Letter

References (8)

1. Teicher E, Vincent I, Bonhomme-Faivre L et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-52.
2. Duclos-Vallée JC, Féray C, Sebagh M et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-17.
3. Hicks C, Gulick RM. Raltegravir: The first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
4. Iwamoto M, Kassahun K, Troyer MD et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008; 48: 209-14.
5. Kassahun K, McIntosh IS, Hreniuk D et al. Metabolism and disposition in humans of raltegravir (MK-0518) an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-63.
6. Programma trapianto di fegato in soggetti con infezione da HIV. Centro Nazionale Trapianti-Commissione Nazionale AIDS, Ministero della Salute, 2004. Available at http://www.ministerosalute.it/imgs/ C_17_normativa_432_allegato.pdf (5 July 2009, date last accessed).
7. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
8. Harris M, Larsen G, Montaner JSG. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008; 22: 1224-6.